Phase 3 N=204 Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — -0.20; -0.94 Percent of HbA1c
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=300 Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
Multiple Sclerosis · Clinically Isolated Syndrome
Primary: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in…
Phase 3 N=25 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Acute Myeloid Leukemia/Transient Myeloproliferative Disorder · Adult Acute Myeloid Leukemia in Remission
Primary: Overall Survival — 6; 6 participants
Phase 3 N=199 Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival — 147; 28 Days — p=<0.000001
Phase 3 N=713 Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -11.6; -14.8; -15.6; -16.5 Units on a scale — p=0.0186
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
Phase 3 N=357 Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -14.2; -15.7 units on a scale — p=0.2492
Phase 3 N=434 Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12.2; -15.3 units on a scale — p=0.0051
Phase 3 N=360 A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children
Asthma
Primary: Change From Baseline in Daytime Composite Symptom Score — 2.73; 2.96; 2.87; -1.38 units on a scale
Phase 3 N=656 A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 — 60.9; 31.5 Percentage of patients — p=<0.001
Phase 3 N=2,133 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T…
Phase 3 N=538 A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Adverse Event (AE) Summary Over Time — 433; 390; 333; 294 Participants
Phase 3 N=319 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Chronic Idiopathic Urticaria
Primary: Change From Baseline to Week 12 in the Weekly Itch Severity Score — -3.63; -6.46; -6.66; -9.40 Units on a scale — p=0.0010
Phase 3 N=1,011 Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia
Primary: Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for…
Phase 3 N=205 Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Meningococcal Disease
Primary: Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥1:8, Upto 13-33 Months After Primary Vaccination With Either MenACWY-CRM or MenC Vaccine — 13…